Integrative Medicine in Nephrology and Andrology最新文献_第3页

Research Progress on the Potential Mechanisms of Acute Kidney Injury and Chronic Kidney Disease Induced by Proton Pump Inhibitors 质子泵抑制剂致急性肾损伤和慢性肾脏疾病潜在机制的研究进展

Integrative Medicine in Nephrology and Andrology Pub Date : 2023-06-01 DOI: 10.1097/IMNA-D-22-00027

Z. Song, Xuezhong Gong

{"title":"Research Progress on the Potential Mechanisms of Acute Kidney Injury and Chronic Kidney Disease Induced by Proton Pump Inhibitors","authors":"Z. Song, Xuezhong Gong","doi":"10.1097/IMNA-D-22-00027","DOIUrl":"https://doi.org/10.1097/IMNA-D-22-00027","url":null,"abstract":"ABSTRACT Proton pump inhibitors (PPIs) are acid-suppressing medications widely used in peptic ulcers; however, their widespread use has led to many adverse renal events. Among these events, the most common form of acute kidney injury (AKI) is acute interstitial nephritis (AIN), which is the clinical manifestation. Several clinical trials and cohort studies have shown a significant relationship between PPIs and AKI induction; however, the pathogenesis of PPIs leading to AKI is unclear. In this paper, we reviewed the potential mechanisms by which PPIs cause AKI and proposed new conjectures. We considered that PPIs led to the development of AKI through a combination of mechanisms. By searching and reviewing PubMed and Embase, a total of 29 studies were finally included and reviewed, and the findings suggested that the mechanisms by which PPIs induce AKI are mainly related to oxidative stress, immune response, inflammatory response, mitochondrial damage, calcium overload, and the induction of cellular necrosis. In addition, tubular cell necrosis can cause tubulointerstitial fibrosis and progressive renal unit loss. Long-term follow-up observations also suggested that PPIs can contribute to AKI progression to chronic kidney disease (CKD). Therefore, we will also explore the potential link between PPIs and CKD.","PeriodicalId":349243,"journal":{"name":"Integrative Medicine in Nephrology and Andrology","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120986783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Discussion of Acute Deficiency Syndrome Theory and its Clinical Application 急性虚证理论及其临床应用探讨

Integrative Medicine in Nephrology and Andrology Pub Date : 2023-06-01 DOI: 10.1097/imna-d-22-00006

Xiang-tong Xu, Wen Zhang, Q. Guo, Yiwen Tu, Yuting Sun, Shuang Zhou, B. Fang

引用次数: 0

Diagnosis of Fibrillary Glomerulonephritis with Positive Immunoglobulin A-κ Deposits Presenting as Membranous Nephropathy Using Immunoelectron Microscopy: A Case Report and Literature Review 免疫球蛋白A-κ阳性沉积表现为膜性肾病的纤维性肾小球肾炎的免疫电镜诊断:1例报告并文献复习

Integrative Medicine in Nephrology and Andrology Pub Date : 2023-06-01 DOI: 10.1097/imna-d-22-00028

Shishi Li, Bing Yan, Fanna Liu

引用次数: 0

Combination Therapy of Low-dose Steroids, Tacrolimus and Mycophenolate Mofetil in Primary Membranous Nephropathy: A Single-center Retrospective Cohort Study 低剂量类固醇、他克莫司和霉酚酸酯联合治疗原发性膜性肾病:一项单中心回顾性队列研究

Integrative Medicine in Nephrology and Andrology Pub Date : 2023-04-29 DOI: 10.1097/IMNA-D-22-00012

Shujuan Zhao, Lining Jia, Chenkai Cui, Zhao Chen, Z. Duan, Jie Gao, Linting Wei, X. Xue, Fuqian Lei, Yanyan Yang, Jing Liu, Peihao Xu, Rongrong Wang, Yang Wei, Xuefei Tian, Rongguo Fu

{"title":"Combination Therapy of Low-dose Steroids, Tacrolimus and Mycophenolate Mofetil in Primary Membranous Nephropathy: A Single-center Retrospective Cohort Study","authors":"Shujuan Zhao, Lining Jia, Chenkai Cui, Zhao Chen, Z. Duan, Jie Gao, Linting Wei, X. Xue, Fuqian Lei, Yanyan Yang, Jing Liu, Peihao Xu, Rongrong Wang, Yang Wei, Xuefei Tian, Rongguo Fu","doi":"10.1097/IMNA-D-22-00012","DOIUrl":"https://doi.org/10.1097/IMNA-D-22-00012","url":null,"abstract":"ABSTRACT Background: Primary membranous nephropathy (pMN) is the most common pathological type of nephrotic syndrome in adults. Therefore, it is imperative to find a better combination therapy with fewer adverse effects for patients with pMN. Methods: This study enrolled 84 patients with biopsy-proven pMN and nephrotic syndrome. Thirty patients in the low-dose multitarget regimen (LDMT) group received low-dose glucocorticoids along with tacrolimus and mycophenolate mofetil, and 54 patients in the prednisone plus intravenous cyclophosphamide regimen (PC) group received corticosteroids plus intravenous cyclophosphamide. The clinical efficacy and safety of the LDMT and PC regimens in treating pMN in adults were analyzed and compared. Results: The cumulative complete remission rate was 6.67%, 56.30%, and 83.14% at the 6th, 12th, and 24th month after treatment in the LDMT group, and 16.67%, 60.84%, and 81.02% in the PC group, respectively (P = 0.620). The generalized estimating equation analysis showed that the longer the treatment duration, the better the improvements in serum albumin and urinary protein levels, and hyperlipidemia (P = 0.0001). However, the serum creatinine levels in both groups remained stable during the treatment period. Meanwhile, the relapse rates were comparable between the two groups (21.43% vs. 22.00%, P = 0.953). Moreover, patients in the LDMT group showed fewer adverse events than those in the PC group (46.67% vs. 72.22%, P = 0.020). Conclusions: These data indicated that the low-dose multitarget regimen, which might be an alternative treatment choice for patients with pMN, had a more favorable safety profile and non-inferior efficacy compared with prednisone plus intravenous cyclophosphamide.","PeriodicalId":349243,"journal":{"name":"Integrative Medicine in Nephrology and Andrology","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125428610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Model of Ischaemia-Induced Renal Interstitial Fibrosis in Mice with Established Diabetes 缺血性糖尿病小鼠肾间质纤维化模型的建立

Integrative Medicine in Nephrology and Andrology Pub Date : 2023-04-21 DOI: 10.1097/IMNA-D-22-00032

F. Ma, G. Tesch, K. Grynberg, E. Ozols, W. Mulley, D. Nikolic-Paterson

{"title":"A Model of Ischaemia-Induced Renal Interstitial Fibrosis in Mice with Established Diabetes","authors":"F. Ma, G. Tesch, K. Grynberg, E. Ozols, W. Mulley, D. Nikolic-Paterson","doi":"10.1097/IMNA-D-22-00032","DOIUrl":"https://doi.org/10.1097/IMNA-D-22-00032","url":null,"abstract":"ABSTRACT Background: Diabetes is a well-established clinical risk factor for the development of acute kidney injury (AKI) following an episode of renal ischaemia. However, we lack a robust animal model to investigate the pathological mechanisms underpinning the increased susceptibility of the diabetic kidney to ischaemia-induced AKI and the transition to chronic kidney disease. The aim of this study was to develop a mouse model in which renal ischaemia induces renal interstitial fibrosis in diabetic mice, but not in control mice. Methods: C57BL6/J mice were made diabetic via 5 low dose streptozotocin injections. 8 weeks later, diabetic mice underwent 12 min of bilateral renal ischaemia and were killed on days 1, 7 or 28 after reperfusion. For comparison, groups of age-matched non-diabetic mice underwent the same renal ischaemia/reperfusion injury (IRI) protocol. Results: Non-diabetic mice developed AKI on day 1 which showed a virtually complete recovery of structure and function by day 7. By contrast, diabetic mice exhibited a state of chronic renal inflammation and developed a much more severe AKI on day 1 after IRI. Diabetic mice showed a marked delay in the repair response on day 7, and exhibited chronic tubular damage, inflammation and robust interstitial fibrosis on day 28. Conclusion: We have developed a mouse model suitable for the dissection of the mechanisms by which diabetes makes the kidney highly susceptible to an ischaemic insult and the transition to chronic kidney disease.","PeriodicalId":349243,"journal":{"name":"Integrative Medicine in Nephrology and Andrology","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115450386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Haikun Shenxi Capsule for Improving Renal Function in Patients with Chronic Kidney Diseases: A Systematic Review and Meta-analysis 海坤参肾胶囊改善慢性肾病患者肾功能的系统评价与meta分析

Integrative Medicine in Nephrology and Andrology Pub Date : 2023-04-20 DOI: 10.1097/IMNA-D-22-00013

Yunling Geng, Zhaocheng Dong, Q. Jia, Pingna Zhang, Jingyi Tang, Yu Ning Liu, Wei Jing Liu

{"title":"Haikun Shenxi Capsule for Improving Renal Function in Patients with Chronic Kidney Diseases: A Systematic Review and Meta-analysis","authors":"Yunling Geng, Zhaocheng Dong, Q. Jia, Pingna Zhang, Jingyi Tang, Yu Ning Liu, Wei Jing Liu","doi":"10.1097/IMNA-D-22-00013","DOIUrl":"https://doi.org/10.1097/IMNA-D-22-00013","url":null,"abstract":"ABSTRACT Haikun Shenxi capsule was widely used for patients with chronic kidney disease (CKD) stages 3–5. This study aimed to systematically evaluate the efficacy and adverse effects of the Haikun Shenxi capsule in the treatment of patients with CKD stages 3–5 (nondialysis-dependent) and provide a reference for clinical application. The Cochrane Library, PubMed, EMBASE, Web of Science, Chinese National Knowledge Infrastructure (CNKI), Wanfang Database, Chongqing VIP Database, and SinoMed Database were searched for randomized-controlled trials applying Haikun Shenxi capsule to treat CKD from their inception date to February 2022. Data extraction and quality assessment were assigned to two researchers, respectively. The risk of bias was assessed by the Cochrane handbook, and Revman5.3 was used for data statistics and analysis. Heterogeneity tests were conducted, and the mean difference (MD) or relative risk (RR) with a 95% confidence interval (95% CI) of the outcomes was presented. Eight randomized controlled trials with 522 patients diagnosed with CKD stages 3–5 (nondialysis-dependent) treated with Haikun Shenxi capsules were included. Compared with the control group, the Haikun Shenxi capsule group showed lower levels of serum creatinine (Scr; MD = −61.14, 95% CI = −68.13 to −54.16, P < 0.00001) and blood urea nitrogen (BUN; MD = −4.21, 95% CI = −5.59 to −2.84, P < 0.00001) and higher creatinine clearance (Ccr; MD = 3.94, 95% CI = 1.47 to 6.42, P = 0.002). No drug-related adverse effects of Haikun Shenxi were found in these studies. The Haikun Shenxi capsule could reduce Scr and BUN levels and increase the Ccr level, thereby improving renal functions of CKD stages 3–5 (nondialysis-dependent) patients without drug-related adverse effects based on conventional therapy.","PeriodicalId":349243,"journal":{"name":"Integrative Medicine in Nephrology and Andrology","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123965889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Combination Therapy of Glucocorticoids, Tacrolimus, and Mycophenolate Mofetil in Primary Membranous Nephropathy Coexisting with Type 2 Diabetes Mellitus: A Retrospective Study 糖皮质激素、他克莫司和霉酚酸酯联合治疗原发性膜性肾病合并2型糖尿病的回顾性研究

Integrative Medicine in Nephrology and Andrology Pub Date : 2023-03-01 DOI: 10.1097/imna-d-22-00010

Yin‐Hui Wang, Chenkai Cui, Xuefei Tian, Li Wang, Xiaotao Ma, Heng Ge, Lin Zhang, Xiaodong Xue, Zhihao Chen, Y. Huo, Hao Wang, Rongguo Fu, Lining Jia

引用次数: 0

Therapeutic Effects of Jin Shui Bao Capsules on Kidney Diseases 金水宝胶囊对肾脏疾病的治疗作用

Integrative Medicine in Nephrology and Andrology Pub Date : 2023-03-01 DOI: 10.1097/imna-d-22-00025

Hongyu Chen, Q. Cheng

引用次数: 0

Efficacy of Huangkui Capsules in the Treatment of Diabetic Kidney Disease: A Systematic Review and Using Network Pharmacology 黄葵胶囊治疗糖尿病肾病疗效的系统评价及网络药理学应用

Integrative Medicine in Nephrology and Andrology Pub Date : 2023-03-01 DOI: 10.1097/imna-d-22-00020

Yunling Geng, Zhaocheng Dong, Ying Wang, Pingna Zhang, Jingyi Tang, P. Li, Renhe Lv, Yu Ning Liu, Wei Jing Liu

引用次数: 0

Immune Response in COVID-19-associated Acute Kidney Injury and Maladaptive Kidney Repair covid -19相关急性肾损伤和不适应肾修复的免疫应答

Integrative Medicine in Nephrology and Andrology Pub Date : 2023-03-01 DOI: 10.1097/imna-d-22-00022

Ying Fu, Z. Dong

引用次数: 0